Reframing HPV in the Exam Room: Communication Strategies That Normalize Prevention

Why HPV Conversations Feel Different

A clinician says, “You can get the HPV vaccine if you’d like, but it’s up to you,” and the parent replies, “Maybe not today.”

Now picture the same parent hearing, “Today I strongly recommend the HPV cancer-prevention vaccine; we’ll give it along with the other routine shots” … and agreeing. Same vaccine. Same family. The difference is a few words and the confidence behind them.

Why does that small shift matter so much? Human papillomavirus (HPV) is both extremely common and strongly associated with multiple cancers, including cervical, anal, penile, vulvar, vaginal, and oropharyngeal cancers.7  Because HPV is sexually transmitted and often asymptomatic, discussions can trigger discomfort, stigma, or shame for patients and caregivers.9 For clinicians, time pressure, the perceived sensitivity of sexual‑health topics, and uncertainty about how to respond to hesitancy can lead to softer or more conditional recommendations.11, 12

These subtle shifts in tone and framing matter. Strong, routine recommendations are consistently associated with higher HPV vaccination uptake than weak or equivocal ones.5, 10, 11 This pattern aligns with health communication models such as the Health Belief Model and Theory of Planned Behavior, which emphasize perceived risk, benefits, and clear cues to action as drivers of preventive behavior.1,2 Reframing HPV prevention as standard, expected cancer prevention rather than a special or sensitive topic can make these conversations easier and more productive for everyone.

Making HPV Prevention Routine, Not Exceptional

Clinicians who present HPV vaccination as a routine adolescent vaccine (offered alongside Tdap and meningococcal vaccines) see higher initiation and completion rates than those who single it out as optional or different.11, 12 A presumptive approach, for example, “Today your child is due for three vaccines, including HPV,” increases acceptance compared with asking whether families are “interested” in HPV vaccination.11 Another landmark randomized trial demonstrated that training physicians to give brief presumptive announcements significantly improved HPV vaccine initiation compared to being trained in participatory conversations or receiving no additional training.6

Describing HPV vaccination as a ‘cancer‑prevention vaccine’ focuses on benefits and severity, which are key constructs of the Health Belief Model5. Short statements that emphasize safety, durability of protection, and long‑term cancer‑prevention benefits help normalize HPV vaccination as part of routine preventive care.

Example phrases

“Today, based on your child’s age, they’re due for three routine vaccines, including the HPV cancer‑prevention vaccine.”

“We give this vaccine to all our patients at this age to protect them from several cancers later in life.”

“This is part of the standard schedule, just like tetanus and meningitis vaccines.”

Try this this week: Choose one presumptive opening line from above and use it with every eligible patient for one clinic session. Jot down how often vaccination is accepted and how comfortable the phrasing feels; adjust words, not the strength of the recommendation.

Key Phrases That Move Patients Toward Action

Brief, clear, and confident language from clinicians is one of the strongest drivers of HPV vaccine uptake.5, 11 Patients and caregivers are more likely to accept vaccination when they hear a strong recommendation linked to cancer prevention and tailored to their age group. Keeping explanations short (one to two sentences) before pausing for questions reduces cognitive overload and allows patients to process a simple, central message – an approach consistent with the Elaboration Likelihood Model, which notes that concise, high‑credibility cues can be persuasive under time pressure.16

Aligning language across the team (front desk, medical assistants, nurses, and clinicians) reinforces a consistent message that HPV vaccination and screening are routine and important.13

“Try this / avoid this” examples

Try: “I strongly recommend the HPV vaccine today to protect you from several cancers.”
Avoid: “You can get it if you’d like, but it’s really up to you.”

Try: “Most of my patients get this at your age; we’ll start the series today.”
Avoid: “Do you have any concerns about HPV or the vaccine before we decide?” (As the opening line; save this for after you’ve given a clear recommendation.)

Try: “Your HPV screening is due; we’ll take care of it as part of today’s visit.”
Avoid: “If you want, we could also do an HPV test today.”

Action step: Pick one “try” phrase and agree as a team to use it consistently for a week. At the end of the week, ask: Did this make conversations shorter, longer, or smoother? What minor wording tweaks would keep the recommendation strong but fit your voice?

Navigating Common Questions in 60 Seconds

Most HPV vaccine-related concerns fall into a small set of themes: safety, fertility, timing relative to sexual activity, and perceived lack of risk.9, 12 Evidence‑aligned communication suggests answering briefly, affirming the question, and returning to a clear recommendation, rather than launching into a long, technical explanation.8, 14 This “acknowledge–answer–anchor” pattern keeps the focus on benefits and action while respecting patient concerns.

Concise responses

Safety: “That’s an important question. Millions of people have taken the vaccine, and it has a very strong safety record; serious side effects are extremely rare. I recommend we give it today.” 4,7

Fertility: “The HPV vaccine does not affect fertility. In fact, by preventing cervical changes and procedures later in life, it may help protect reproductive health.”17

Sexual activity: “We give it at this age because it works best before exposure, but it still provides protection even if someone is already sexually active.”

Perceived low risk: “We can’t predict future exposure, and HPV is very common. Vaccinating now is the best way to reduce your long‑term cancer risk.”

Action step: As a team, choose the two concerns you hear most often and agree on one 1–2 sentence response for each. Post them on a cue card in work areas so no one has to improvise under time pressure.

Putting It Into Practice Now

Translating communication principles into daily practice works best when teams rehearse together and clarify shared language. Social Cognitive Theory emphasizes that self‑efficacy grows through modeling and rehearsal; brief role‑plays and cue cards are simple ways to build that confidence.3, 14 Research on announcement training, structured practice delivering short, presumptive recommendations (“Today we’re starting the HPV vaccine series”), shows that providers who practice presumptive recommendation approaches report greater confidence, time-savings, and perceived effectiveness compared to those trained in participatory conversation styles.

Example huddle exercise

Step 1: One person plays a hesitant parent (“I’ve heard this vaccine is new and I’m not sure it’s safe”), another plays the clinician using a presumptive recommendation plus a 60‑second response.

Step 2: Swap roles, then debrief as a team: What phrases felt natural? What words felt awkward? What alternatives do we want on our cue card?

Step 3: Decide on one presumptive opening line and two concise responses that everyone will use for the next week.

Posting a one‑page “HPV talk” cue card in staff areas with key phrases, “try this / avoid this” examples, and 60‑second responses helps reinforce new habits in real‑world conditions. Aligning these communication changes with existing vaccination workflows and navigation efforts strengthens the link between awareness, recommendation, and completed vaccination or screening.13, 15

Conclusion

Normalizing HPV prevention in the exam room is less about delivering a perfect script and more about building consistent, confident habits across the care team. By treating HPV vaccination and screening as routine cancer prevention, using brief but strong recommendations, and preparing concise responses to common questions, clinicians can shift conversations from hesitation to action in just a few moments of each visit. When these micro‑level communication practices are aligned with systems for navigation and follow‑up, every “Ask about HPV” becomes a reliable gateway to completed vaccination, timely screening, and fewer HPV‑related cancers over time.

References
  1. Ajzen I. The theory of planned behavior. Organizational Behavior and Human Decision Processes. 1991;50(2):179–211. doi:10.1016/0749-5978(91)90020-T.
  2. Alyafei A, Easton-Carr R. The Health Belief Model of Behavior Change. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024 May 19. Available at: https://www.ncbi.nlm.nih.gov/books/NBK606120/.
  3. Bandura A. Social cognitive theory of self-regulation. Organizational Behavior and Human Decision Processes. 1991;50(2):248–287. doi:10.1016/0749-5978(91)90022-L.
  4. Bednarczyk RA. Addressing HPV vaccine myths: practical information for healthcare providers. Human Vaccines & Immunotherapeutics. 2019;15(7–8):1628–1638. doi:10.1080/21645515.2019.1565267.
  5. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Preventive Medicine. 2007;45(2–3):107–114. doi:10.1016/j.ypmed.2007.05.013.
  6. Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements versus conversations to improve HPV vaccination coverage: a randomized trial. Pediatrics. 2017;139(1):e20161764. doi:10.1542/peds.2016-1764.
  7. Centers for Disease Control and Prevention. Human Papillomavirus (HPV) and Cancer. Atlanta, GA: CDC, National Center for Chronic Disease Prevention and Health Promotion. Available at: https://www.cdc.gov/cancer/hpv/.
  8. Constable C, Ferguson K, Nicholson J, Quinn GP. Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: A systematic review. CA Cancer J Clin. 2022 Nov;72(6):561-569. doi: 10.3322/caac.21753. Epub 2022 Aug 15. PMID: 35969145.
  9. Ferrer HB, Trotter C, Hickman M, Audrey S. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health. 2014;14:700. doi:10.1186/1471-2458-14-700.
  10. Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiology, Biomarkers & Prevention. 2015;24(11):1673–1679. doi:10.1158/1055-9965.EPI-15-0326.
  11. Gilkey MB, McRee A-L. Provider communication about HPV vaccination: a systematic review. Human Vaccines & Immunotherapeutics. 2016;12(6):1454–1468. doi:10.1080/21645515.2015.1129090.
  12. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatrics. 2014;168(1):76–82. doi:10.1001/jamapediatrics.2013.2752.
  13. Kornides ML, Fontenot HB, McRee A-L, Gilkey MB. Importance of a team approach to recommending the human papillomavirus vaccination. Journal of the American Association of Nurse Practitioners. 2018;30(7):368–372. doi:10.1097/JXX.0000000000000064.
  14. Malo TL, Hall ME, Brewer NT, Lathren CR, Gilkey MB. Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation. Implementation Science. 2018;13(1):57. doi:10.1186/s13012-018-0743-8.
  15. National HPV Vaccination Roundtable. HPV Cancer Prevention Starts With Your Practice: An Action Guide for Small Practices. 2024. Available at: https://hpvroundtable.org/wp-content/uploads/2024/10/Cancer-Prevention-Through-HPV-Vaccination-An-Action-Guide-for-Small-Practices.pdf.
  16. Petty RE, Cacioppo JT. The Elaboration Likelihood Model of persuasion. Advances in Experimental Social Psychology. 1986;19:123–205. doi:10.1016/S0065-2601(08)60214-2.
  17. Schmuhl NB, Mooney KE, Zhang X, Cooney LG, Conway JH, LoConte NK. No association between HPV vaccination and infertility in U.S. females 18–33 years old. Vaccine. 2020;38(24):4038–4043. doi:10.1016/j.vaccine.2020.03.035.

Tags